Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 5 studies | 69% ± 17% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 42% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 68800.85 | 226 / 226 | 99% | 849.44 | 401 / 406 |
spleen | 100% | 214.21 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 88% | 57.54 | 1063 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 75% | 14.96 | 247 / 328 | 11% | 0.58 | 20 / 178 |
blood vessel | 83% | 86.53 | 1103 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 79% | 66.50 | 732 / 929 | 0% | 0 | 0 / 0 |
breast | 76% | 30.36 | 348 / 459 | 1% | 0.12 | 8 / 1118 |
lung | 70% | 13.35 | 407 / 578 | 2% | 0.06 | 18 / 1155 |
uterus | 65% | 17.81 | 110 / 170 | 3% | 0.15 | 15 / 459 |
adrenal gland | 56% | 22.52 | 144 / 258 | 1% | 0.04 | 3 / 230 |
intestine | 46% | 10.88 | 440 / 966 | 3% | 1.53 | 18 / 527 |
thymus | 48% | 9.02 | 311 / 653 | 1% | 0.03 | 6 / 605 |
ovary | 48% | 11.10 | 86 / 180 | 0% | 0.00 | 1 / 430 |
bladder | 43% | 5.33 | 9 / 21 | 3% | 0.08 | 13 / 504 |
skin | 39% | 9.91 | 707 / 1809 | 3% | 0.09 | 13 / 472 |
lymph node | 0% | 0 | 0 / 0 | 38% | 0.80 | 11 / 29 |
heart | 38% | 10.46 | 324 / 861 | 0% | 0 | 0 / 0 |
stomach | 33% | 6.41 | 119 / 359 | 4% | 0.20 | 12 / 286 |
esophagus | 34% | 6.30 | 488 / 1445 | 3% | 0.33 | 5 / 183 |
prostate | 35% | 6.24 | 86 / 245 | 1% | 0.02 | 6 / 502 |
muscle | 26% | 4.83 | 207 / 803 | 0% | 0 | 0 / 0 |
kidney | 17% | 2.06 | 15 / 89 | 8% | 1.23 | 76 / 901 |
brain | 19% | 3.12 | 509 / 2642 | 3% | 0.07 | 20 / 705 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.04 | 1 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030212 | Biological process | hyaluronan metabolic process |
GO_0072562 | Cellular component | blood microparticle |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
GO_0005509 | Molecular function | calcium ion binding |
GO_0030246 | Molecular function | carbohydrate binding |
GO_0005540 | Molecular function | hyaluronic acid binding |
GO_0005515 | Molecular function | protein binding |
Gene name | ITIH1 |
Protein name | Inter-alpha-trypsin inhibitor heavy chain H1 (ITI heavy chain H1) (ITI-HC1) (Inter-alpha-inhibitor heavy chain 1) (Inter-alpha-trypsin inhibitor complex component III) (Serum-derived hyaluronan-associated protein) (SHAP) Inter-alpha-trypsin inhibitor heavy chain 1 |
Synonyms | IGHEP1 |
Description | FUNCTION: May act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization, synthesis and degradation of hyaluronan which are essential to cells undergoing biological processes.; FUNCTION: Contains a potential peptide which could stimulate a broad spectrum of phagocytotic cells. |
Accessions | ENST00000480409.1 B5MCP1 ENST00000428133.5 ENST00000405128.3 F8WAS2 H7C0N0 ENST00000484844.2 H7C5I0 P19827 ENST00000273283.7 [P19827-1] ENST00000537050.5 [P19827-3] |